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Investigators at nearly 700 sites enrolled over 20 000 patientsin the Prevention Regimen for Effectively Avoiding Second
Strokes (PRoFESS) trial. As clinicians, we recognized an im-
portant practical question that was unanswered by indirect
comparisons. We understood that the combination of aspirin
with dipyridamole better prevented stroke recurrence than aspi-
rin but incurs some intolerance. We believed that clopidogrel
monotherapy offered a smaller advantage over aspirin but at
greater cost. When the race began, the betting favored the
aspirin–dipyridamole combination on cost and efficacy grounds.
PRoFESS gave us the answer we should have desired. We
need an array of strategies so that we can tailor treatment to
our patients and respond to restrictions caused by side effects.
In practice, poorer adherence to treatment resulting from
intolerance to dipyridamole may have balanced any greater
inherent efficacy, rendering the aspirin– dipyridamole com-
bination equal to clopidogrel. Drs Selim and Algra offer
helpful insights into the interpretation of the antiplatelet
results in the context of the previous trials. Both agree that
whatever the scientific reasons behind the results of
PRoFESS, clopidogrel has been found equivalent to the
aspirin and dipyridamole combination.
Telmisartan conferred no additional benefit, raising ques-
tions over the optimal timing for initiation of antihyperten-
sives after stroke and over the claimed benefits, beyond blood
pressure-lowering, of angiotensin receptor blockers. Drs
McInnes and Selim both suggest that the relatively short
duration of the trial militated against a definitive result. This
may be fair criticism, although a counterproposal may be that
PRoFESS has excluded any benefit of clinically useful extent.
Regardless, clopidogrel is likely now to be more widely
considered, whereas telmisartan will be discounted for early
blood pressure reduction. PRoFESS has widened our choice
of first-line antiplatelet strategy without adding to our pa-
tients’ pill count, and in this regard, it has been a straightfor-
ward win for the patient.
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